11 results about "Hypotaurine" patented technology

There is provided a method for diagnosing a subject with early onset muscle atrophy, said method comprising: obtaining a biosample from the subject; and assaying the biosample for one or more biomarkers, said one more biomarkers are taurine, proline, citrulline, trigonelline, thymidine, ornithine, glutamate, L-pyroglutamic acid, creatinine, adenine, nicotinamide, 2-methylhippuric acid, maltol, L-arginine, hypotaurine, L-glutamine, homogentisic acid, methylhistidine, oxoglutaric acid, xanthine, L-carnitine, succinate, or a combination thereof; and identifying the subject with early onset muscle atrophy on the basis of a deviation in the one or more of said one more biomarkers.

The invention relates to the technical field of NK cell culture, and discloses an NK culture medium containing hypotaurine and application of the NK culture medium to improvement of NK cell proliferation and killing activity, and the NK culture medium comprises a basic NK cell culture medium and hypotaurine; the basic NK cell culture medium does not contain hypotaurine and comprises amino acid, vitamins, inorganic salt, trace elements, D-glucose and sodium pyruvate. When the basic NK cell culture medium is an RPMI1640 culture medium, the concentration of the hypotaurine is 0.1-1 mM; when the basic NK cell culture medium is an IMDM culture medium, the concentration of the hypotaurine is 0.4-4 mM. According to the scheme, the hypotaurine is added into the basic NK cell culture medium to obtain the NK culture medium, the NK culture medium can increase the number of NK cells when the NK cells are cultured in vitro, and the killing activity of the cultured NK cells on tumor cells is remarkably improved.

The invention relates to the technical field of nephritis medicine, in particular to an AAGN disease metabolism marker, a kit and application of the AAGN disease metabolism marker. In the blood or urine metabolism marker, the blood metabolism marker is prepared from one or more of 6-methyl nicotinamide, hypo-sulphosarcosine, guanosine, allopurinol, 8-hydroxy-2 '-deoxyguanosine, triglyceride or lysophosphatidylcholine; the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl-leucyl-phenylalanine, alloandrosterone, enterodiphenol and p-coumarin, and the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl- The metabolic marker combination and the kit are used for evaluating the disease activity state of a patient suffering from ANCA-related glomerulonephritis (AAGN), and have good repeatability, stability and biological correlation.

The present invention relates to a method for isolating taurine from a fermentation broth after microbial fermentation of a production strain, comprising the following isolation steps in the given order: (i) isolating a fermentation supernatant by separating biomass from the fermentation broth, (ii) precipitating taurine from the fermentation supernatant by adding a water-miscible solvent 1 (e.g., ethanol), (iii) isolating the taurine precipitate and dissolving it in solvent 2 (water), (iv) crystallizing the dissolved taurine, and (v) isolating and optionally drying the crystallized taurine, whereby the isolated taurine has a purity of >80% (w / w). Thus, a simple method for isolating fermentatively prepared, highly pure taurine is provided.

The application discloses a chrysanthemum stem and leaf active extract with improved fish heavy metal poisoning and a preparation method thereof. The chrysanthemum stem and leaf active extract is compounded by a chrysanthemum stem and leaf crude polysaccharide part and a chrysanthemum stem and leaf phenolic ketone part. The pharmacodynamic experiment results show that the chrysanthemum stem and leaf active extract has a good improvement effect on fish heavy metal poisoning. The chrysanthemum stem and leaf active extract can not only improve pathological changes such as heart and liver granuloma, kidney tubular cast, intestinal cavity expansion and gill lamella shedding caused by heavy metal poisoning, but also improve metabolic dysfunction such as taurine and hypotaurine metabolic disorder, pyruvic acid metabolic abnormality, tricarboxylic acid cycle disorder, glycolysis and gluconeogenesis disorder caused by heavy metal poisoning. The preparation method has reasonable whole preparation process design, can realize waste utilization, extends a chrysanthemum industry chain, expands a chrysanthemum resource utilization approach, is helpful to quality improvement and efficiency increase and green development of the chrysanthemum industry, and provides support for prevention and treatment of heavy metal poisoning.

The application discloses application of cell endogenous metabolites in preparation of medicines for treating and / or preventing aging. The cell endogenous metabolites are any one or combination of phosphocreatine, hypotaurine and / or phosphoethanolamine. The application finds that phosphocreatine, hypotaurine and phosphoethanolamine can effectively restore cell growth, reduce cell SA-beta-Gal staining intensity, improve cell mitochondrial function and increase ATP yield, restore cell mitochondrial membrane potential, alleviate damage caused by cell oxidative stress and premature aging, and also prolong the life of nematodes and restore exercise capacity in the middle of aging. Meanwhile, the three metabolites have a synergistic effect, and by adjusting the matching concentration of the three metabolites, the same cell protection effect can be achieved by mixed administration. Since the endogenous metabolites are accurate, efficient and safe, the three cell endogenous metabolites provided by the application can be used for preparing anti-aging medicines.

The invention relates to the technical field of bioengineering, in particular to crassostrea gigas FMO1 protein as well as a preparation method and application thereof. The invention provides a method for efficiently preparing crassostrea gigas FMO1 protein. According to the invention, identification of a key step of crassostrea gigas taurine synthesis, namely a key taurine metabolism gene FMO1 sequence and function generated by oxidation of sub-taurine, is realized for the first time. Therefore, the Crassostrea gigas FMO1 candidate gene sequence is accurately identified, and meanwhile, the Crassostrea gigas FMO1 in-vitro recombinant protein is efficiently and massively prepared. The invention also provides a method for detecting the activity of the crassostrea gigas FMO1 in-vitro recombinant protein for catalyzing the oxidation reaction of the hypotaurine. According to the method, the activity of the FMO1 protein and the generation of the taurine can be evaluated by monitoring the consumption of NADPH (Nicotinamide Adenine Dinucleotide Phosphate) in a reaction system.

The invention discloses a cysteine sulfinate decarboxylase mutant with improved enzymatic activity, and belongs to the field of gene engineering and enzyme engineering. According to the present invention, cysteine sulfinate decarboxylase derived from aedes aegypti is adopted as a parent enzyme, and site-directed mutagenesis modification is performed on the amino acid sequence of the cysteine sulfinate decarboxylase through rational design so as to obtain the mutant capable of significantly improving the enzyme activity; according to the amino acid sequence of the mutant, compared with a parent enzyme, threonine at the 410th site is replaced with proline, and threonine at the 498th site is replaced with tryptophan. A determination result shows that the specific enzyme activity of the two-site mutant is 4.19 times that of a parent enzyme. The cysteine sulfinic acid decarboxylase mutant can efficiently catalyze cysteine sulfinic acid to generate hypotaurine through decarboxylation, provides a key enzyme preparation for green and efficient synthesis of taurine, and has important application prospects in the fields of food additive preparation, medical intermediate synthesis, biological catalytic reaction system construction and the like. And a foundation is laid for industrial application of the cysteine sulfinate decarboxylase.

The invention relates to application of 5, 7-dimethoxy coumarin in preparation of a medicine for treating metabolic syndrome, and belongs to the technical field of biological medicine. The invention discloses a new application of 5, 7-dimethoxy coumarin in treatment of metabolic syndrome for the first time, and the 5, 7-dimethoxy coumarin can regulate intestinal flora composition and serum metabolic spectrum, mainly relates to key pathways such as steroid hormone biosynthesis, taurine and hypotaurine metabolism and the like, so that the alleviation or treatment of metabolic disorder is realized in multiple aspects, and the treatment effect is good. A brand new medicine development strategy is provided for comprehensive prevention and treatment of the metabolic syndrome.

This invention relates to the field of NK cell culture technology, and discloses an NK culture medium containing taurine and its application in improving NK cell proliferation and killing activity. The medium includes a basal NK cell culture medium and taurine; the basal NK cell culture medium does not contain taurine and includes amino acids, vitamins, inorganic salts, trace elements, D-glucose, and sodium pyruvate. When the basal NK cell culture medium is RPMI_1640 medium, the concentration of taurine is 0.1~1mM; when the basal NK cell culture medium is IMDM medium, the concentration of taurine is 0.4~4mM. This method obtains an NK culture medium by adding taurine to the basal NK cell culture medium. This NK culture medium not only increases the number of NK cells during in vitro culture, but also significantly enhances the killing activity of the cultured NK cells against tumor cells.

This disclosure relates to eukaryotic cell culture media useful in the production of recombinant proteins from cultured cell lines. The eukaryotic cell culture media comprise integrated stress response inhibitor (ISRIB), and / or hypotaurine and / or increased level of iron, and / or suramin. The disclosure also provides methods using said eukaryotic cell culture media, e.g. for culturing mammalian cells with enhanced product titer, and / or growth, and / or viability and / or for producing a recombinant protein of comparable or better product quality by culturing a eukaryotic cell line that comprises a polynucleotide encoding the recombinant protein in said media under conditions suitable for production of the polypeptide. Also provided are use of the eukaryotic cell culture media for the production of a recombinant protein from a cultured cell line comprising a polynucleotide encoding the recombinant protein.